Now in its sixth year, WuXi Global Forum 2018 takes place during the J.P. Morgan Healthcare Conference, with industry thought leaders discussing rapid advancements and changes impacting the industry, from the most disruptive therapeutic interventions to artificial intelligence to the evolving global regulatory landscape.
China’s Food and Drug Administration has introduced landmark reforms in 2017 to accelerate new drug approval, which are likely to be a game changer for companies that want to bring innovative products to the world’s second-largest pharmaceutical market more quickly.
Moderator: Steve Yang, EVP, CBO and CSO, WuXi AppTec
Ruyi He, Chief Scientist, CDE/CFDA
The hurdles could not be higher for young companies working on diseases that have taken their toll even amongst the most experienced drug hunters. This panel takes a closer look at four startup all-stars on how they are tackling tough diseases through unique lenses, and launching a new generation of disruptive therapeutic intervention.
Moderator: Kristina Burow, Managing Director, ARCH Venture Partners
Barbara Weber, CEO of Tango Therapeutics; Venture Partner of Third Rock Ventures
Sandy Macrae, President and CEO, Sangamo Therapeutics
Geoffrey von Maltzahn, Co-Founder and Chief Innovation Officer, Kaleido Biosciences
Bill Doyle, Executive Chairman of Novocure; Managing Director of WFD Ventures
Data. Artificial Intelligence. Deep Learning. What do they really mean? How will they change the future of drug discovery and development? How will they change the way we predict, prevent, diagnose, and treat diseases? And, are we ready?
Moderator: David Beier, Managing Director, Bay City Capital
Jessica Mega, Chief Medical Officer, Verily Life Sciences
Vijay Pande, General Partner, Andreessen Horowitz
Atul Butte, CEO, Karius
Alex Zhavoronkov, CEO, Insilico Medicine
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances, and Head of PR and Corporate Communications. Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS), and a member of BayHelix. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.
James C. Greenwood is President and CEO of the Biotechnology Innovation Organization (BIO) in Washington, D.C. BIO represents 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 countries worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, and industrial & environmental biotechnology products. BIO also produces the annual BIO International Convention, the world’s largest annual gathering of the biotechnology industry. Greenwood represented Pennsylvania’s Eighth District in the U.S. House of Representatives from 1993 to 2005. Since 2005, his deep relationships on Capitol Hill and knowledge of politics and policy have substantially raised BIO’s profile and enhanced the organization’s advocacy work. During his time in Congress, he was a senior member of the Energy and Commerce Committee and widely viewed as a leader on health care and the environment. He crafted legislation to reform the Food and Drug Administration, and he led the fight in Congress to allow stem-cell research to be conducted by U.S. scientists to treat disease. From 2001 to 2004, Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation’s infrastructure; and waste and fraud in federal government agencies. Prior to his election to Congress, Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992).
Dr. Ge Li is one of the most influential leaders in the global biopharma R&D industry. He pioneered an integrated R&D service model and the open-access R&D enabling platform model with the conviction that more efficient and cost-effective R&D should be at the core of better medicines for patients, and that “every drug can be made and every disease can be treated.” As the company’s Chairman and CEO, Dr. Li has led WuXi’s rapid growth from four employees and a single Chemistry lab of 7,000 square feet in December 2000 to a transformative global R&D powerhouse enabling over 3,000 collaborative partners worldwide. Dr. Li earned his Bachelor’s degree in Chemistry from Peking University and his doctoral degree in Organic Chemistry from Columbia University.
Mr. Edward Hu is currently CFO and CIO at WuXi AppTec. In this capacity, Mr. Hu manages the company’s finance, investments, mergers and acquisitions, joint ventures, and new business and capability building. In addition, Mr. Hu is Head of WuXi Corporate Venture Fund, spearheading the fund’s investment activities and portfolio management. Mr. Hu previously served WuXi’s COO and CFO for five years until April 2014. Prior to joining WuXi, Mr. Hu was SVP and COO at Tanox, responsible for operations, finance, IT, project management and strategic planning, and managed the acquisition of Tanox by Genentech in 2007. He also held positions at Merck & Co., Inc. as a Senior Financial Analyst and later in Business and Financial Planning at Biogen, Inc. (n/k/a Biogen Idec, Inc.), where he managed the business planning of Biogen’s R&D and clinical operations organizations, and provided project planning and analysis support to key drug development project teams. Mr. Hu completed his Ph.D. work, all but dissertation, in Biophysics and Biochemistry at Carnegie Mellon University, where he also received his M.B.A.
James (Jay) Bradner, M.D., joined Novartis on January 1, 2016 and became President of the Novartis Institutes for BioMedical Research (NIBR) on March 1, 2016. He is a member of the Executive Committee of Novartis. Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States. He was also associate director of the Center for the Science of Therapeutics at the Broad Institute of MIT and Harvard. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 150 scientific publications and 30 US patent applications. Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women’s Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.
Dr. Vessey serves as President of Research and Early Development. He joined Celgene in January 2015 as Senior Vice President, Translational Development. Before joining Celgene, Dr. Vessey was Senior Vice President of Early Development and Discovery Sciences at Merck. During his ten years with Merck, Dr. Vessey was responsible for numerous drug development programs and served as Senior Vice President, Early Development and Discovery Sciences, Senior Vice President, Respiratory and Immunology Franchise and Vice President, Drug Discovery and Informatics. Prior to Merck, he spent five years at GlaxoSmithKline in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases. Dr. Vessey graduated from Oxford University with degrees in Physiological Sciences (MA), Clinical Medicine (BM, BCH) and a DPhil (PhD) in Molecular Immunology. He is an elected Fellow of the Royal College of Physicians.
Bruce Booth is a partner and focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Bruce is currently chairman of AvroBio, Kymera Therapeutics, Hotspot Therapeutics, miRagen Therapeutics, Nimbus Therapeutics, and Rodin Therapeutics, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics, Unum Therapeutics, and Zafgen (NASDAQ:ZFGN). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), and a number of other ventures. Bruce serves as an advisor in various capacities to UCB, Shire, Pfizer, and Takeda. He also serves on the board of the National Venture Capital Association. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Dr. Steve Yang is Executive Vice President and Chief Business Officer and Chief Strategy Officer of WuXi AppTec. He is also WuXi’s Head of Research Service Division. His responsibilities include management of multiple business units and corporate strategic planning and commercial operation. WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device R&D capability and technology open access platform company with operations in China, US, and Europe. Dr. Yang is a pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer’s global R&D strategic management group based in the United States. Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude from Michigan Technological University. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese life science business leaders, and served as the chairman of the board for two terms.
Dr. Ruyi He is the Chief Scientist at the Center for Drug Evaluation at the Chinese Food and Drug Administration (CFDA). Dr. He joined CFDA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years. Dr. Ruyi He joined the US Center for Drug Evaluation and Research (CDER) at the US FDA in 1999 as a Medical Officer in the Division of Gastrointestinal and Coagulation Drug Products. He became a Medical Team Leader in 2003 and served as the Acting Deputy Division Director later. He has chaired several working groups that were tasked with drafting and finalizing guidelines for industry. Dr. Ruyi He has received many awards since he joined the FDA, including the FDA Excellence in Review Science Award, CDER Leadership Excellence Award, CDER Excellence in Mentoring Award, FDA Award of Merit, and the Department of Health and Human Services Secretary’s Award for Distinguished Service. Dr. Ruyi He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. He received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) in Bethesda, Maryland. He is a licensed, board-certified physician in Internal Medicine in the US.
Kristina Burow is a Managing Director with ARCH Venture Partners and is focused on the creation and development of biotechnology, pharmaceutical and agbiotechnology companies. Since joining ARCH in 2002 Ms. Burow has played a significant role in the creation and development of a number of companies. Ms. Burow is a Director of Vividion Therapeutics, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals (SNNA), Metacrine, Scholar Rock, Unity Biotechnology, AgBiome, AgTech Accelerator and Vir Biotechnology. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene). Ms. Burow has participated in a number of other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH – acquired by Allergan), Ikaria (acquired by Mallinckrodt) and was a co-founder and board member of Sapphire Energy. Prior to joining ARCH Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spin-outs from GNF. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
Barbara Weber joined Third Rock Ventures in 2015. In that role, she was interim CMO for Neon Therapeutics from launch in 2015 until Sept 2017, and played a leadership role in creating Relay Therapeutics, launched in March 2016. However, her passion building for a cancer therapeutics company based on recent advances in cancer genetics led to Tango Therapeutics. Tango launched with a $55M Series A from TRV in March 2017, with Barbara as the interim CEO. In September 2017, Barbara accepted the position as the permanent CEO. Tango has a fully-operational target discovery platform, two drug discovery programs and a score of targets that will make a substantial difference to patients. Prior to joining Third Rock, Barbara was SVP and Global Head of Oncology Translational Medicine at Novartis from 2009- 2015, and VP Oncology Discovery and Translational Medicine at GlaxoSmithKline from 2005-2009. Previously, Barbara was Professor of Medicine and Genetics at The University of Pennsylvania, leading a clinical and translational research program in cancer genetics. Barbara is an elected member of the American Association of Physicians and the American Society for Clinical Investigation, of which she served as President in 2005. Barbara has served on the Board of Directors of both ASCO and AACR. She is a graduate of the University of Washington School of Medicine, completed her residency in Internal Medicine at Yale University and her fellowship in Medical Oncology at the Dana-Farber Cancer Institute.
Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr. Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.
Geoffrey von Maltzahn is a leading innovator and entrepreneur in the microbiome and biotechnology and is a co-founder of companies that have achieved over $4 billion in private and public market capitalization. He is a partner at Flagship Pioneering and has co-founded multiple biotech companies, including Seres Therapeutics, Indigo Agriculture, Axcella Health, and Sienna Biopharmaceuticals. He recently served as the President of Indigo, where he led the creation of the world’s largest plant microbiome database and development of the company’s first commercial products. Von Maltzahn is an inventor on more than 100 patents and patent applications in biotech, nutrition and microbiome-based technologies and has been recognized with numerous awards, including the prestigious Lemelson-MIT student prize, given to the most innovative student at MIT. Von Maltzahn’s innovations have been profiled by the Economist, CNN, Fortune, Scientific American, Popular Science and others. He received his Ph.D. from MIT in the Harvard-MIT Division of Health Sciences and Technology; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.
Mr. Doyle serves as the Executive Chairman of Novocure Ltd. (NASDAQ:NVCR), a cancer therapy company; and as the Executive Chairman of Blink Health Ltd., a private technology company providing fair access to prescription drugs. Mr. Doyle has been the managing director of WFD Ventures LLC, a private venture capital firm he co-founded, since 2002. Prior to 2002, Mr. Doyle was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and was vice president, Licensing and Acquisitions. While at Johnson & Johnson, Mr. Doyle was also chairman of the Medical Devices Research and Development Council, and Worldwide president of Biosense-Webster, Inc. Earlier in his career, Mr. Doyle was a management consultant in the healthcare group of McKinsey & Company. Mr. Doyle holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology (M.I.T.) and an M.B.A. from Harvard Business School. Mr. Doyle serves on the Board of Harvard Business School and on the M.I.T. Corporation Visiting Committee for Undergraduate Education.
David Beier, JD is a Managing Director of Bay City Capital and has been with the firm since 2013. He is a globally recognized leader in health care policy, pricing, intellectual property, government affairs, regulatory affairs, health care economics, and product commercialization. Prior to Bay City, he has held senior management positions at Amgen and Genentech, the two largest biotechnology companies in the world. Mr. Beier served in the White House as the Chief Domestic Policy Advisor to Vice President Al Gore during the Clinton Administration. He has testified before Congress and the Federal Trade Commission, has written numerous law review articles and technical legal works, and is regularly invited to author expert OpEds. He currently serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission, as a Fellow of the Center for Global Enterprise, and teaches as an Adjunct Lecturer at the Haas School of Business at UC Berkeley. He is also an advisor to the Parker Institute on Cancer Immunotherapy and member and chair of its Strategic Advisory Group. In addition, Mr. Beier is a Senior Fellow at the USC Schaeffer Center for Health Policy & Economics. He received his JD from Albany Law School at Union University and his undergraduate degree and Colgate University. He is admitted to practice law in New York and the District of Columbia.
Jessica leads Verily’s healthcare team, which informs and studies Verily’s products, creates health platforms, and translates them into systems that improve outcomes. She is a cardiologist who trained and practiced at Massachusetts General Hospital and Brigham and Women’s Hospital. As a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group, Jessica directed large, international clinical trials. She received her A.B. from Stanford University, M.D. from Yale University School of Medicine and M.P.H. from the Harvard School of Public Health.
Vijay Pande is a general partner at Andreessen Horowitz where he leads the firm’s investments in companies at the cross section of biology and computer science. Previously, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, and also the director of the Biophysics program at Stanford. Vijay is the founder of the Folding@Home Distributed Computing Project for disease research that pushes the boundaries of the development and application of computer science techniques into biology and medicines. While at Stanford, Vijay co-founded Globavir Biosciences, which discovered cures for Dengue Fever and Ebola. Vijay received a BA in Physics from Princeton University and a PhD in Physics from MIT. He was awarded the DeLano Prize in Computation, Guinness World Record for Folding@Home, ACS Thomas Kuhn Paradigm Shift Award, and MIT TR100.
Atul Butte, MD, PhD is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and inaugural Director of the Institute for Computational Health Sciences (ichs.ucsf.edu) at the University of California, San Francisco (UCSF). Dr. Butte is also the Executive Director for Clinical Informatics across the six University of California Medical Schools and Medical Centers. Dr. Butte has authored over 200 publications, with research repeatedly featured in the New York Times, Wall Street Journal, and Wired Magazine. Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the Obama Administration as an Open Science Champion of Change for promoting science through publicly available data. Dr. Butte is also a founder of three investor-backed data-driven companies: Personalis, providing medical genome sequencing services, Carmenta (acquired by Progenity), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte is a principal investigator of three major programs: the California Initiative to Advance Precision Medicine; ImmPort, the clinical and molecular data repository for the National Institute of Allergy and Infectious Diseases; and the California Precision Medicine Consortium, helping recruit tens of thousands of participants into President Obama’s Precision Medicine Initiative. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD from Harvard Medical School and MIT.
Dr. Kertesz co-founded Karius in 2014 to bring the novel pathogen detection technology he and colleagues developed at Stanford closer to the bedside. Based in Redwood City, California, Karius now provides a Next-Generation Sequencing based test that is able to identify over 1,250 pathogens from a single blood draw. Prior to founding Karius, Dr. Kertesz was the CEO and co-founder of Moleculo, a long-reads DNA sequencing company, which was acquired by Illumina in late 2012. Dr. Kertesz earned an MS in computer science from Tel Aviv University and a PhD in computational biology from the Weizmann Institute of Science. He went on to join the Quake lab at Stanford University for his postdoctoral research in bioengineering, where he developed methods for investigating the genetic diversity of human viruses.
Dr. Zhavoronkov specializes in the development of the next-generation artificial intelligence and Blockchain technologies for drug discovery, biomarker development and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties and launched multiple biomarker initiatives including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies, NeuroG, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and diversity.AI initiative. Since 2012 he published over 70 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”. He is also the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe’s largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a Master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.
Peter Winter is a seasoned science journalist based in Ottawa, Canada and has been writing about and analyzing the progress of the biotech industry since the early 1980s. He is editor of BioWorld Insight, a weekly news service that tracks the financial and business trends of the biopharmaceutical industry. He was the founder and editor of Canadian Biotech News, a weekly newsletter that served the industry for 20 years. He received his undergraduate degree from the University of London and is the recipient of the Science Journalism Laureate Award from Purdue University (2009).